Definium Therapeutics (DFTX) Equity Average (2020 - 2026)

Definium Therapeutics (DFTX) has 7 years of Equity Average data on file, last reported at $305.6 million in Q1 2026.

• Equity Average for Q1 2026 came in at $305.6 million, up 31.65% year-over-year; the trailing twelve-month figure through Mar 2026 was $305.6 million (up 31.65% YoY), and the FY2025 annual result was $286.9 million, up 79.54% from the prior year.
• Equity Average climbed to $305.6 million in Q1 2026 per DFTX's latest filing, from $231.5 million in the prior quarter.
• Over five years, Equity Average peaked at $305.6 million in Q1 2026 and troughed at $87.1 million in Q4 2023.
• A 5-year average of $174.4 million and a median of $152.3 million in 2022 frame the typical range for Equity Average.
• The sharpest annual moves came in 2023 and 2024: Equity Average slumped 42.82% in 2023, then surged 189.26% in 2024.
• A 5-year view of Equity Average shows it stood at $152.3 million in 2022, then sank by 42.82% to $87.1 million in 2023, then soared by 189.26% to $251.8 million in 2024, then fell by 8.08% to $231.5 million in 2025, then soared by 32.03% to $305.6 million in 2026.
• Business Quant data shows DFTX's Equity Average at $305.6 million in Q1 2026, $231.5 million in Q4 2025, and $158.0 million in Q3 2025.